Search results for "Baseline Dyspnea Index"

showing 2 items of 2 documents

Determinants of Dyspnea in Patients with Different Grades of Stable Asthma

2003

Dyspnea is a main feature of symptomatology in asthma, and its perception does not necessarily correlates well with airway obstruction. The aim of this study was twofold: (1) to identify factors determining the subjective degree of dyspnea in patients with different grades of stable bronchial asthma and (2) to compare various clinical methods existing for grading dyspnea. The investigation comprised 153 outpatients with stable asthma. The parameters studied were the following: demographic characteristic of subjects, baseline dyspnea score by means of three clinical instruments (baseline dyspnea index [BDI], Medical Research Council [MRC] scale, and modified Borg scale), asthma severity, sta…

AdultLung DiseasesMalePulmonary and Respiratory Medicinemedicine.medical_specialtyActivities of daily livingAdolescentSeverity of Illness IndexQuality of lifeHumansImmunology and AllergyMedicineDepression (differential diagnoses)AgedAsthmabusiness.industryMental DisordersRespiratory diseaseAge FactorsBaseline Dyspnea IndexMiddle AgedAirway obstructionmedicine.diseaseAsthmarespiratory tract diseasesDyspneaPediatrics Perinatology and Child HealthPhysical therapyAnxietyFemalemedicine.symptombusinessJournal of Asthma
researchProduct

Indacaterol vs tiotropium in COPD patients classified as GOLD A and B

2015

SummaryIntroductionAccording to current GOLD strategy, patients with COPD classified as groups A and B may be treated with inhaled bronchodilators, either long-acting β2-agonist (LABA) or long-acting muscarinic antagonist (LAMA). However, there is little guidance on which class of agent is preferred and a lack of prospective data to differentiate the two.MethodsIn this study, we performed post-hoc analyses of pooled data from two prospective, controlled clinical trials comparing the LABA indacaterol and LAMA tiotropium in 1422 patients with moderate airflow limitation and no history of exacerbations in the previous year. This population fits the definitions of GOLD A and B groups and could …

MalePulmonary and Respiratory MedicineEfficacyPopulationINDEXESQuinolonesOBSTRUCTIVE PULMONARY-DISEASEPulmonary Disease Chronic ObstructiveHumansMedicineCOPDCOHORTProspective StudiesGOLDTiotropium BromideeducationDYSPNEAIndacateroleducation.field_of_studyCOPDDose-Response Relationship Drugbiologybusiness.industryTiotropiumONCE-DAILY INDACATEROLMuscarinic antagonistForced Expiratory Flow RatesBaseline Dyspnea IndexMiddle AgedLamabiology.organism_classificationmedicine.diseaseBronchodilator Agentsrespiratory tract diseasesClinical trialTreatment OutcomeAnesthesiaIndansCohortIndacaterolFemalebusinessCLINICAL METHODSFollow-Up Studiesmedicine.drugRespiratory Medicine
researchProduct